Researchers will unveil MoleScope™, an innovative hand-held tool that uses a smartphone to monitor skin for signs of cancer, at the World Congress of Dermatology conference in Vancouver June 9-13.
The product, from the start-up venture, MetaOptima Technology Inc., enables people to monitor their moles and skin health, share images with family and healthcare providers and eventually, connect skin specialists with people online.
MoleScope™ comprises a mini-microscope that attaches to a smartphone, an app (iOS, Android, or web compatible) and a cloud-based analytical platform called DermEngine™. Once people take high-quality, high-resolution images of suspicious moles or skin abnormalities, they can archive images and communicate concerns with others.
The product is expected to provide healthcare benefits in communities without access to medical specialists and in those with long waitlists as people can self-monitor their moles and track changes over time.
The company has developed two versions of the product: a consumer version expected to retail at $149; and a more expensive professional version being presented at the World Congress of Dermatology meeting.
MoleScope™ has received approval from Health Canada, is FDA registered as a Class 1 medical device in the U.S. and has just received the CE Mark in the EU. TGA approval in Australia is expected shortly. The company is initiating an early adopter program with qualified dermatologists and receiving strong interest from potential distributors and channel partners throughout the world.
Based on material originally posted by Simon Fraser University.